Synthetic Biologics, Inc. (SYN)

$0.986

-0.07 (-6.98%)
Rating:
Recommendation:
Neutral
Symbol SYN
Price $0.986
Beta 1.316
Volume Avg. 0.20M
Market Cap 15.622M
Shares () -
52 Week Range 0.97-4.6
1y Target Est -
DCF Unlevered SYN DCF ->
DCF Levered SYN LDCF ->
ROE -26.49% Sell
ROA -21.59% Sell
Operating Margin -
Debt / Equity 33.49% Neutral
P/E -
P/B 0.25 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SYN news


Mr. Steven Shallcross
Healthcare
Biotechnology
American Stock Exchange

Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.